Wall Street Zen Downgrades Pharvaris (NASDAQ:PHVS) to Sell

by · The Markets Daily

Pharvaris (NASDAQ:PHVS – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

A number of other brokerages have also weighed in on PHVS. Oppenheimer increased their price target on Pharvaris from $44.00 to $50.00 and gave the stock an “outperform” rating in a research note on Thursday, December 4th. Wedbush increased their target price on Pharvaris from $27.00 to $30.00 and gave the stock an “outperform” rating in a research report on Thursday, November 13th. Guggenheim raised their price target on Pharvaris from $32.00 to $39.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Zacks Research raised shares of Pharvaris from a “strong sell” rating to a “hold” rating in a research note on Monday, August 18th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a report on Wednesday, October 8th. Nine investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $40.56.

View Our Latest Report on Pharvaris

Pharvaris Price Performance

Shares of NASDAQ PHVS opened at $24.16 on Friday. The company has a market cap of $1.26 billion, a PE ratio of -7.53 and a beta of -2.80. Pharvaris has a 12 month low of $11.51 and a 12 month high of $29.80. The company has a 50-day simple moving average of $23.84 and a 200-day simple moving average of $21.94.

Pharvaris (NASDAQ:PHVS – Get Free Report) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.08. On average, analysts anticipate that Pharvaris will post -2.71 EPS for the current year.

Hedge Funds Weigh In On Pharvaris

Hedge funds and other institutional investors have recently modified their holdings of the company. Wellington Management Group LLP acquired a new stake in Pharvaris during the 3rd quarter worth approximately $43,282,000. Paradigm Biocapital Advisors LP lifted its position in Pharvaris by 72.7% during the third quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company’s stock valued at $45,796,000 after buying an additional 772,583 shares in the last quarter. Balyasny Asset Management L.P. purchased a new stake in Pharvaris during the third quarter worth approximately $15,613,000. Commodore Capital LP increased its position in shares of Pharvaris by 26.5% in the third quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock worth $60,341,000 after acquiring an additional 507,043 shares in the last quarter. Finally, General Atlantic L.P. increased its position in shares of Pharvaris by 6.6% in the third quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock worth $200,380,000 after acquiring an additional 500,000 shares in the last quarter.

About Pharvaris

(Get Free Report)

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.

See Also